MSTN and cancer: Together with data demonstrating that blockade of the myostatin/ActRIIB pathway is highly beneficial in models of cancer-induced cachexia [3–6], our results indicate that ActRII blockade might be beneficial in cachectic cancer patients which are or have been exposed to chemotherapies.